Table 3.
Results from crudea linear mixed models in weighted study population (N=457 subjects; N=1611 observations) representing percent change in plasma angiogenic biomarker concentration in association with an interquartile range increase in urinary phthalate metabolite concentration.
| sFlt-1 | PlGF | sFlt-1/PlGF ratio | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| percent change (95% CI) | p | percent change (95% CI) | p | percent change (95% CI) | p | |
| MEHP | −1.83 (−5.98, 2.50) | 0.402 | 3.74 (−1.94, 9.74) | 0.202 | −3.80 (−10.9, 3.89) | 0.323 |
| MEHHP | 1.71 (−2.57, 6.19) | 0.439 | −5.55 (−10.8, 0.05) | 0.052 | 9.01 (0.76, 17.9) | 0.032 |
| MEOHP | 1.19 (−2.93, 5.49) | 0.576 | −3.47 (−8.73, 2.09) | 0.217 | 6.62 (−1.24, 15.1) | 0.101 |
| MECPP | 2.08 (−2.56, 6.93) | 0.386 | −8.42 (−13.8, −2.67) | 0.005 | 12.3 (3.32, 22.0) | 0.006 |
| ΣDEHP | 1.88 (−2.68, 6.64) | 0.425 | −6.58 (−12.1, −0.69) | 0.029 | 10.4 (1.56, 20.0) | 0.020 |
| MBzP | 1.33 (−4.39, 7.39) | 0.656 | 1.79 (−5.06, 9.14) | 0.618 | 0.87 (−8.17, 10.8) | 0.857 |
| MBP | −0.62 (−5.80, 4.86) | 0.821 | 0.98 (−5.20, 7.56) | 0.762 | 0.83 (−7.37, 9.77) | 0.848 |
| MiBP | −2.08 (−8.15, 4.39) | 0.519 | 2.61 (−5.32, 11.2) | 0.530 | −2.98 (−13.0, 8.19) | 0.586 |
| MEP | −0.28 (−5.17, 4.85) | 0.912 | 6.79 (0.13, 13.9) | 0.046 | −4.42 (−12.4, 4.29) | 0.310 |
| MCPP | −2.94 (−6.92, 1.20) | 0.162 | −2.19 (−7.41, 3.33) | 0.430 | 1.30 (−5.98, 9.15) | 0.734 |
| BPA | 7.08 (2.04, 12.4) | 0.006 | −3.68 (−9.82, 2.88) | 0.265 | 12.3 (2.62, 22.8) | 0.012 |
a
Models were adjusted for urinary specific gravity and gestational age at sample collection and included random intercepts and slopes for each study subject. Abbreviations: sFlt-1, soluble fms-like tyrosine kinase-1; PlGF, placental growth factor. Note: P-values were not corrected for multiple comparisons.